Our researchers have produced work which has directly influenced the national health agenda by impacting NHS guidelines and policies and setting up cutting edge approved treatment centres.
Examples from BRC3 include:
- III Theme Director Professor Emma Morris and Professor Siobhan Burns have pioneered the use of allogeneic haematopoietic stem cell therapy for adults with inherited immunodeficienices resulting in a new NHS England commissioning policy (NHS England, 170129P, 2019). This policy will guarantee routinely commissioned transplants for adults with rare diseases.
- Led by Professor Stuart Taylor, METRIC, the largest prospective multicentre diagnostic accuracy study of MRI and ultrasound in Crohn’s disease to date has directly influenced NHS practice, international (European Crohn’s and Colitis organisation) and national (British Society of Gastroenterology) clinical guidelines.
- UCLH has been designated an official treatment centre for NICE-approved commissioned CAR T cell therapies in adolescents and adults.
- In Partnership with Imperial College London and hVIVO, the COVID-19 Human Challenge Programme, funded via the UK Government’s Vaccines Taskforce, is being run by a leading UCL clinical academic, Professor Sir Mike Jacobs, at the Royal Free London NHS Foundation Trust. Additionally, III funded scientists from the UCL division of Infection and Immunity will carry out cutting edge research on the immune response. The work has been co-ordinated by III theme director Professor Emma Morris (Director, UCL Division of Infection & Immunity) and Professor Robert Heyderman (Head, UCL Research Department of Infection).
